ClinicalTrials.gg
RecruitingNCT06216470Updated May 29, 2025

Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

A Phase 2 interventional study of VIR-3434 in Hepatitis B, Chronic, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Hepatitis B, Chronic with a site in Canada — 2 open to participants now, 4 under way, none of them phase 3. Hepatitis B, Chronic · Canada.

Planned enrollment
51st of 54
15 · median 110
Started
2024
with 2 others
Phase 2
27 of 59
2 open now
Registered
56th of 59
by date
Lead sponsor
4 of 59
University Health Network, Toronto

Among the 59 studies in Hepatitis B, Chronic with a site in Canada, this one is the 51st largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2024, is one of 27 in phase 2, and was the 56th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

2 of the 59 studies in Hepatitis B, Chronic with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hepatitis B, Chronic with a site in Canada, or all of them as a file.
02

Study summary

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.

The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body.

This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.

Read the detailed description

The objective of this study is to evaluate the vaccinal effect of VIR-3434 in chronic HBeAg-negative hepatitis B (CHB) patients suppressed on nucleos(t)ide analogue therapy. Total 15 patients will be enrolled at single site.

The participants will receive VIR-3434 300 mg subcutaneous injection every 4 weeks x 48 weeks and then follow up for 48 weeks. Total three Fine-needle aspiration (FNA) procedure will be performed during the study: before treatment, 3 days after the first injection and 3 days after the week24 injection.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 to ≤65 years
  2. Chronic infection with evidence of HBsAg-positivity x > 6 months
  3. Quantitative HBsAg 300 - 10,000 IU/mL
  4. On stable nucleos(t)ide therapy >1 year
  5. HBV DNA \< 60 IU/mL on 2 occasions at least 12 weeks apart
  6. ≤ 45 U/L on 2 occasions at least 12 weeks apart
  7. Female subjects must have a negative pregnancy test or confirmation of status. Women of (WOCBP) must have a negative pregnancy test at screening and on Day 1, cannot be breast feeding, and must be willing to use highly effective methods of 14 days before study drug administration through the study participation. Female subjects must also agree to refrain from egg donation and in vitro fertilization from the time of study drug administration through the study participation.
  8. Male subjects with female partners of child-bearing potential must agree to meet 1 of the following contraception requirements from the time of study drug administration through the study participation: documentation of vasectomy or azoospermia, or male condom use plus partner use of 1 of the contraceptive options listed for contraception for WOCBP. Male subjects must also agree to not donate sperm from the time of study drug administration through the study participation.
  9. Able and willing to sign

Exclusion criteria

Exclusion Criteria:

  1. History of cirrhosis as evidenced by prior Liver Elastography (Fibroscan) > 12 kilopascals (kPa), liver (F4 by METAVIR) or clinical evidence of decompensation (ascites, hepatic encephalopathy)
  2. History of or current hepatocellular carcinoma
  3. Virus (HCV) RNA or anti-Hepatitis D Virus (HDV) positive
  4. co-infection
  5. Pregnancy or lactation
  6. (ALT) > 45 U/L
  7. History of chronic liver disease other than aside from fatty liver documented only on US
  8. Use of peginterferon therapy for HBV infection within past 12 months
  9. Use of chronic medications at a dose equivalent to 10 mg daily of prednisone or greater within past 6 months
  10. Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in previous 6 months, other than non-melanoma skin cancer in previous 5 years, immunodeficiency syndrome
  11. Subject has received any drug (including any investigational vaccines) within 90 days or 5 half-lives (whatever is longer) before screening for this study or is currently enrolled in an investigational study
  12. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments, such as liver FNAs
  13. count \< 120,000,000,000/L
  14. The (INR) > 1.3
  15. > 40 µmol/L
  16. \< 110 g/dL for women or 120 g/dL for men
  17. estimated (eGFR) \< 45 cc/min
  18. Alpha Fetoprotein (AFP) > 50 ng/mL
  19. Prior liver or other solid organ transplantation
  20. Patients on anticoagulation therapy or with any bleeding diathesis
  21. Patients with hemoglobinopathy (thalassemia, sickle cell disease etc)
  22. Other significant liver disease: alcoholic liver disease, hepatitis, hemochromatosis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson Disease or alpha-1 antitrypsin deficiency - as documented in clinical history
  23. Unable to provide
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    VIR-3434

    VIR-3434 300 mg subcutaneous injection every 4 weeks\*48 weeks

    Drug: VIR-3434

Interventions

  • VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).

06

What researchers measure

Primary outcomes

  1. Change in log Quantitative HBsAg

    Time frame: from baseline through study completion, an average of 2 year

Secondary outcomes

  1. Absolute and change of Hepatitis B Virus (HBV) RNA

    Time frame: from baseline through study completion, an average of 2 year

  2. Absolute and change of HBV core-related Ag

    Time frame: from baseline through study completion, an average of 2 year

  3. Proportion of subjects with HBsAg loss

    Time frame: from baseline through study completion, an average of 2 year

  4. HBeAg seroconversion

    Proportion of subject with HBeAg seroconversion

    Time frame: from baseline through study completion, an average of 2 year

  5. Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) with study treatment

    Frequency of AEs and SAEs with VIR-3434 administration in combination with NA therapy for CHB

    Time frame: from baseline through study completion, an average of 2 year

  6. Frequency of AEs and SAEs due to hepatic FNA

    Time frame: from baseline through study completion, an average of 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2029, 69 months after the start.

Of 87 phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 22, 2024
StartActual
Mar 13, 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216470
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Mar 13, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
May 29, 2025

Study contacts

Jordan Feld, MD
Contact
jordan.feld@uhn.ca
416-340-4584
Jiayun Chen
Contact
jiayun.chen@uhn.ca
416-340-4800 ext. 6854
Jordan Feld, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobevibart

Start the discussion